Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: A comprehensive mutation profiling from 5125 Chinese cohorts

British Journal of Cancer

Volumn 110, Issue 11, 2014, Pages 2812-2820

  Li, S ^a   Li, L ^a   Zhu, Y ^b   Huang, C ^a   Qin, Y ^a   Liu, H ^a   Ren Heidenreich, L ^c   Shi, B ^d   Ren, H ^e   Chu, X ^f   Kang, J ^g   Wang, W ^g   Xu, J ^c   Tang, K ^c   Yang, H ^c   Zheng, Y ^c   He, J ^c   Yu, G ^c   Liang, N ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b AIR FORCE GENERAL HOSPITAL   (China)

^c SurExam Bio Tech Co Ltd   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^e GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

^f CHINESE PLA GENERAL HOSPITAL   (China)

^g NAVY GENERAL HOSPITAL   (China)

Author keywords

double and triple mutations; liquid chip technology; multiplex testing; non small cell lung cancer; somatic mutations

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; B RAF KINASE GENE; CANCER CHEMOTHERAPY; CHILD; CHINESE; CONTROLLED STUDY; E545K GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE K RAS; PHENOTYPE; PIK3CA GENE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; SOMATIC MUTATION; T790M GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHILD; CHILD, PRESCHOOL; CHINA; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84901590009     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.210     Document Type: Article

References (37)

1. Age Group of Lung Cancer Diagnosed (2000-2007) http://www.aboutcancer. com/lung1b.htm.
2. American Cancer Society (2011) Cancer Facts and Figures 2009. http://ww2. cancer.org/downloads/STT/500809web.pdf.
3. Asahina H, Yamazaki K, Kinoshita I, Yokouchi H, Dosaka-Akita H, Nishimura M (2006) Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 54(3): 419-422.
4. Besaratinia A, Pfeifer GP (2008) Second-hand smoke and human lung cancer. Lancet Oncol 9(7): 657-666.
5. Chaft JE, Arcila ME, Paik PK, Lau C, Riely GJ, Pietanza MC, Zakowski MF, Rusch V, Sima CS, Ladanyi M, Kris MG (2012) Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 11(2): 485-491.
6. D'Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG (2011) Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 29(15): 2066-2070.
7. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8): 753-762.
8. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, Brzostowski EB, Riely GJ, Kris MG, ZakowskiMF, Ladanyi M (2012) Molecular epidemiology of EGFR and KRAS mutations in 3026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 18(22): 6169-6177.
9. Engelman JA, Janne PA (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14(10): 2895-2899.
10. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA (2006) Allelic dilution obscures detection of a biologically significant resistance mutation in EGFRamplified lung cancer. J Clin Invest 116(10): 2695-2706.
11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
12. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8): 786-792.
13. Li G, Luo X, He J, Zhu Z, Yu G, Qin H, Zeng T, Liu Z, Wu S, Xu J, Ren-Heidenreich L (2011) A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PIK3CA from formalin-fixed and paraffin-embedded slides containing tumor tissue. Clin Chem Lab Med 49(2): 191-195.
14. Lin L, Bivona TG (2012) Mechanisms of resistance to epidermal growth factor receptor inhibitors and novel therapeutic strategies to overcome resistance in NSCLC patients. Chemother Res Pract 2012: 817297.
15. Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L (2011) Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 6(4): 707-715.
16. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21): 2129-2139.
17. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, Viola P, Pullara C, Mucilli F, Buttitta F (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29(26): 3574-3579.
18. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F (2005) EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23(4): 857-865.
19. Masago K, Fujita S, Irisa K, Kim YH, Ichikawa M, Mio T, Mishima M (2010) Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC4ATC in exon 20 (S768I). Jpn J Clin Oncol 40(11): 1105-1109.
20. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W (2012) Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci USA 109(31): E2127-E2133.
21. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W (2011) New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 17(17): 5530-5537.
22. Paik PK, ArcilaME, Fara M, Sima CS, Miller VA, Kris MG, LadanyiM, Riely GJ (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29(15): 2046-2051.
23. PaoW,Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36): 13306-13311.
24. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1): e17.
25. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418(6901): 934.
26. Riely GJ, Kris MG, Rosenbaum D,Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14(18): 5731-5734.
27. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL (1987) Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317(15): 929-935.
28. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M. Spanish Lung Cancer Group (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10): 958-967.
29. Sasaki H, Kawano O, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y (2006) Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 133(2): 203-206.
30. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M (2009) EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15(14): 4554-4560.
31. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ,Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ, Bos JL, Rodenhuis S (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323(9): 561-565.
32. Smits AJ, Kummer JA, Hinrichs JW, Herder GJ, Scheidel-Jacobse KC, Jiwa NM, Ruijter TE, Nooijen PT, Looijen-Salamon MG, Ligtenberg MJ, Thunnissen FB, Heideman DA, de Weger RA, Vink A (2012) EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell Oncol (Dordr) 35(3): 189-196.
33. Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R (2010) Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol 5(1): 23-28.
34. Toyooka S, Kiura K, Mitsudomi T (2005) EGFR mutation and response of lung cancer to gefitinib. N Engl J Med 352(20): 2136.
35. Wu S, Zhu Z, He J, Luo X, Xu J, Ren-Heidenreich L (2010) A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples. Clin Chem Lab Med 48(8): 1103-1106.
36. Xu J, He J, Yang H, Luo X, Liang Z, Chen J, Cai Z, Xu J, Ren-Heidenreich L (2011) Somatic mutation analysis of EGFR, KRAS, BRAF and PIK3CA in 861 patients with non-small cell lung cancer. Cancer Biomark 10(2): 63-69.
37. Zhang L, Yang H, Zhao Y, Liu W, Wu S, He J, Luo X, Zhu Z, Xu J, Zhou Q, Ren-Heidenreich L (2012) Detection of EGFR somatic mutations in non-small cell lung cancer (NSCLC) using a novel mutant-enriched liquidchip (MEL) technology. Curr Drug Metab 13(7): 1007-1011.